[{"address1": "1560 Trapelo Road", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "781 786 8230", "fax": "781 786 8866", "website": "https://www.dyne-tx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 143, "companyOfficers": [{"maxAge": 1, "name": "Ms. Susanna Gatti High M.B.A.", "age": 55, "title": "Chief Operating Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 754104, "exercisedValue": 0, "unexercisedValue": 2408104}, {"maxAge": 1, "name": "Dr. Jonathan  McNeill M.D.", "age": 38, "title": "Chief Business Officer", "yearBorn": 1985, "fiscalYear": 2023, "totalPay": 662344, "exercisedValue": 0, "unexercisedValue": 1701801}, {"maxAge": 1, "name": "Mr. John G. Cox M.B.A.", "age": 60, "title": "CEO, President & Director", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Romesh  Subramanian Ph.D.", "age": 58, "title": "Co-Founder & Advisor", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 565170, "exercisedValue": 0, "unexercisedValue": 284933}, {"maxAge": 1, "name": "Mr. Richard William Scalzo M.B.A.", "age": 37, "title": "Senior VP and Head of Finance & Administration", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Najim M.B.A.", "title": "Chief Technical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Oxana  Beskrovnaya Ph.D.", "age": 62, "title": "Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 631076, "exercisedValue": 0, "unexercisedValue": 1167727}, {"maxAge": 1, "name": "Ms. Amy  Reilly", "age": 49, "title": "Senior VP and Head of Corporate Communications & Investor Relations", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Wilson", "age": 51, "title": "Senior VP & Head of Legal", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kate  Mitchell", "title": "VP & Head of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1717200000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 33.91, "open": 33.76, "dayLow": 32.78, "dayHigh": 34.03, "regularMarketPreviousClose": 33.91, "regularMarketOpen": 33.76, "regularMarketDayLow": 32.78, "regularMarketDayHigh": 34.03, "beta": 1.062, "forwardPE": -11.04886, "volume": 807039, "regularMarketVolume": 807039, "averageVolume": 1168300, "averageVolume10days": 1097730, "averageDailyVolume10Day": 1097730, "bid": 33.85, "ask": 33.95, "bidSize": 100, "askSize": 200, "marketCap": 3373601536, "fiftyTwoWeekLow": 6.4, "fiftyTwoWeekHigh": 36.6, "fiftyDayAverage": 29.2573, "twoHundredDayAverage": 19.4766, "currency": "USD", "enterpriseValue": 2537089024, "floatShares": 73161114, "sharesOutstanding": 99457600, "sharesShort": 10114816, "sharesShortPriorMonth": 9633663, "sharesShortPreviousMonthDate": 1714435200, "dateShortInterest": 1717113600, "sharesPercentSharesOut": 0.1017, "heldPercentInsiders": 0.00466, "heldPercentInstitutions": 0.98543, "shortRatio": 6.41, "shortPercentOfFloat": 0.121300004, "impliedSharesOutstanding": 99457600, "bookValue": 5.489, "priceToBook": 6.1796317, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -257399008, "trailingEps": -3.98, "forwardEps": -3.07, "enterpriseToEbitda": -9.603, "52WeekChange": 2.2521572, "SandP52WeekChange": 0.24598539, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "DYN", "underlyingSymbol": "DYN", "shortName": "Dyne Therapeutics, Inc.", "longName": "Dyne Therapeutics, Inc.", "firstTradeDateEpochUtc": 1600349400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "bf98e34f-5989-3e23-b14d-e7c60952a6b7", "messageBoardId": "finmb_608699906", "gmtOffSetMilliseconds": -14400000, "currentPrice": 33.92, "targetHighPrice": 56.0, "targetLowPrice": 41.0, "targetMeanPrice": 46.67, "targetMedianPrice": 45.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 453547008, "totalCashPerShare": 5.19, "ebitda": -264208000, "totalDebt": 26617000, "quickRatio": 20.281, "currentRatio": 21.828, "debtToEquity": 5.568, "returnOnAssets": -0.4098, "returnOnEquity": -0.71501, "freeCashflow": -152868368, "operatingCashflow": -219787008, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-27"}]